Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PARG | Q86W56 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 5/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954983 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL2411241 | 0.81 | SMN1; SMN2 (0.61) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL11992039 | 0.77 | ALDH1A1 (0.63) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL21240889 | 0.77 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL7144241 | 0.77 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL2854064 | 0.77 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL15688099 | 0.77 | CTSL (0.64) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL2192047 | 0.76 | KDM4E (0.54) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL2192046 | 0.76 | KDM4E (0.54) | ALDH1A1LMNAKMT2ATDP1PARG | |
| SCHEMBL3940478 | 0.76 | LMNA (0.76) | ALDH1A1LMNAKMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2025-02-27 | — | — | US | disclosed |
| CN-118339145-A | Bicyclic fused ring derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-07-12 | — | — | CN | disclosed |
| EP-4397655-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023055124-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사유한양행 | 2023-04-06 | — | — | WO | disclosed |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| EP-3955923-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | The Regents Of The University Of Michigan (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2009129401-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2079696-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066308-A1 | BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LOX, XDH, IL4I1 | ALDH1A1 571/4885LMNA 834/4885KMT2A 707/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | ALDH1A1 4653/4885LMNA 4781/4885KMT2A 2786/4885 |
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | ALDH1A1 150/4885LMNA 3437/4885KMT2A 1428/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | ALDH1A1 3887/4885LMNA 2252/4885KMT2A 1162/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | ALDH1A1 608/4885LMNA 4139/4885KMT2A 914/4885 |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | ALDH1A1 4147/4885LMNA 3685/4885KMT2A 1934/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ALDH1A1 649/4885LMNA 3182/4885KMT2A 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.